Protalix Biotherapeutics, Inc. Reports 2017 Second Quarter Results and Provides Corporate Update

Published: Aug 09, 2017

CARMIEL, Israel, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the six months ended June 30, 2017 and provided a corporate update.

Back to news